INDV — Indivior Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$40.50
Market Cap
$4.79B
52W High
$42.81
52W Low
$30.11
ADV30
1,864,227
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
| Sep 2025 | 314,000,000 | 231,000,000 | 44,000,000 | 42,000,000 | 1,416,000,000 | 445,000,000 | 1,623,000,000 |
| Jun 2025 | 302,000,000 | 250,000,000 | 71,000,000 | 18,000,000 | 1,452,000,000 | 510,000,000 | 1,710,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-267,000,000
Investing CF
$-29,000,000
Financing CF
$-52,000,000
CapEx
$-82,000,000
Dividends Paid
—
Buybacks
$-126,000,000
EPS Diluted TTM
$2.19
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-280,000,000
Inventory
$152,000,000
Receivables
$285,000,000
ST Investments
—
EBIT TTM
$335,000,000
Pretax Income TTM
$295,000,000
Interest Exp TTM
$40,000,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,290,000,000
EBITDA
$475,000,000
Free Cash Flow
$44,250,000
Enterprise Value
$5,369,380,864
Total Cash
$175,000,000
Total Debt
$509,000,000
Shares Out
118,204,585
Trailing EPS
$1.95
Book Value
$-1.18
ROE
—
ROA
22.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | — | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | — | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | — | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | — | -4,000,000 |
TTM Snapshot
Revenues TTM
$299,000,000
NetIncome TTM
$-97,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,758,000,000
Forward EPS
$4.14
Max Pain — expiry 2026-08-21
max pain strike: $35.00 · spot: $40.50 · call oi: 18,770 · put oi: 383
Expected Move to 2026-08-21:
±$7.15
(17.65%) —
implied range
$33.35 –
$47.65
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.89B | $45.41 | — |
| MANE | Veradermics, Inc | $5.00B | $119.60 | — |
| TNGX | Tango Therapeutics, Inc. | $5.06B | $31.06 | — |
| VKTX | Viking Therapeutics, Inc. | $4.51B | $38.86 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $4.49B | $26.22 | — |
News headlines (Yahoo Finance, 1h cache)
Indivior’s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV)
2026-06-30 03:14 · Yahoo
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
2026-06-29 15:15 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
2026-06-29 12:55 · Yahoo
Bull of the Day: Neurocrine Biosciences (NBIX)
2026-06-29 08:00 · Yahoo
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
2026-06-26 14:43 · Yahoo
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
2026-06-26 14:28 · Yahoo
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
2026-06-26 08:59 · Yahoo
IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects
2026-06-25 15:24 · Yahoo
Reasons Why Investors Should Consider Betting on Indivior Stock
2026-06-25 13:27 · Yahoo
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
2026-06-25 12:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.